The latest market report published by Credence Research, Inc. “Global Intravitreal Injectables Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global Intravitreal injectables market is keen to register stable growth at a CAGR of 4.8% from 2018 to 2026.
Intravitreal injection is useful in administering controlled drugs in the vitreous chamber near the eye to ensure maximum drug effectiveness and reduced systemic toxicity. Patients usually feel pressure and no discomfort after injection. Few possible adverse events have been documented with intraocular injections, such as intraocular inflammation, retinal detachment, hypotony, etc., which function as a potential limiting factor for market growth of intravitreal injectables.
Macular degeneration and diabetic retinopathy are disorders that occur in elderly populations usually after 40 years of age. The risk factors that cause the pathophysiology of AMD and DR are old age, obesity, diabetes, smoking and genetics. When left untreated, they can result in temporary to permanent vision loss depending on the severity of clinical manifestations. Bacterial eye infections, such as endophthalmitis and retinitis, will display rampant growth in developing nations due to increased air and water pollution and increased incidences of eye trauma.
Since its introduction in 2006, anti-VEGF medicines such as Avastin and Lucentis have gained substantial prominence among ophthalmologists worldwide and are currently the first line of treatment for eye disorders such as neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR). This conducts anti-angiogenic action, preventing the leakage of blood vessels developing under the retina. Corticosteroids are used as an adjuvant therapy for the treatment of inflammation associated with bacterial eye infection and are recommended along with antibiotics and antifungal drugs for the treatment of endophthalmitis and retinitis.
North America currently represents 37% of the market share and is the leading geographic division of the intravitreal injectbles industry. The key factors that contribute to its positive market growth are the growing incidence of age-related macular degeneration in the population aged 40 years and above and an attractive refund scenario for intravitreal injections. Europe has a market share of 26% due to a growing number of patients diagnosed with diabetic retinopathy and a favorable regulatory environment for the use of intravitreal injectables for the treatment of ophthalmic disorders.
Asia Pacific with a market share of 20% is looking forward to create a huge impact in the near future owing to rising prevalence of bacterial eye infections such as endophthalmitis and retinitis and presence of subsidiaries of leading pharmaceutical giants such as Allergan, Inc., Novartis AG and Genetech, Inc. etc.
Pharmaceutical giants competing to maintain stronghold in Intravitreal Injectables market are Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F.Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc. and Valeant Pharmaceuticals International, Inc.
Key Market Movements:
Rising incidence of ophthalmic complications causing partial or complete vision loss
Excellent pharmacodynamic and pharmacokinetic drug profile of anti-VEGF as an Intravitreal injectable to treat AMD, DR and ocular vein occlusions
Affordable reimbursement scenario for intravitreal injectables in developed and developing nations